In combination with dabrafenib for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. <1yr or <8kg: not established.

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839] Technology appraisal guidance Dabrafenib, trametinib or both for ...